Form 4: Intra-Cellular Therapies EVP Suresh K. Durgam Reports Disposition of Shares and Derivative Securities Following Merger with Johnson & Johnson

Suresh K. Durgam, EVP and Chief Medical Officer of Intra-Cellular Therapies, reports the disposition of common stock, stock options, and restricted stock units due to the merger with Johnson & Johnson, where Intra-Cellular Therapies became a wholly-owned subsidiary of Johnson & Johnson.

Summary

• This Form 4 filing reports changes in beneficial ownership for Suresh K. Durgam, EVP and Chief Medical Officer of Intra-Cellular Therapies, Inc.
• The changes are a result of the merger between Intra-Cellular Therapies and Johnson & Johnson, which became effective on April 2, 2025.
• As a result of the merger, Intra-Cellular Therapies became a wholly-owned subsidiary of Johnson & Johnson.
• Durgam disposed of 42,913 shares of common stock at a price of $132 per share, receiving cash consideration.
• Outstanding stock options with exercise prices below $132 were canceled and converted into the right to receive a cash payment equal to the difference between $132 and the exercise price, multiplied by the number of shares underlying the option.
• Stock options with exercise prices equal to or exceeding $132 were canceled for no consideration.
• Restricted stock units (RSUs) were canceled and converted into the right to receive $132 per unit, with some RSUs granted in 2025 payable at the original vesting date.
• Performance stock units (PRSUs) were canceled and converted into the right to receive $132 per unit, assuming target performance levels were met.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The merger provides a clear exit for shareholders at a premium, but it also eliminates future independent growth potential. The executive's disposition of shares is a natural consequence of the merger.

Positives

• The merger provides a clear exit strategy for shareholders at a defined price of $132 per share.
• Executives with stock options below the merger consideration price receive a cash payment for their options.
• Holders of RSUs and PRSUs receive cash payments, providing liquidity.

Negatives

• Executives lose potential future upside from stock appreciation as the company is now a wholly-owned subsidiary.
• Stock options with exercise prices at or above $132 were canceled for no consideration, resulting in a loss for the holders.

Risks

• The document does not explicitly mention any risks, but the merger eliminates the possibility of future independent growth for Intra-Cellular Therapies.
• Future performance is now tied to Johnson & Johnson's strategic decisions.

Future Outlook

The future outlook for Intra-Cellular Therapies is now tied to Johnson & Johnson's strategic plans and operations as a wholly-owned subsidiary.

Industry Context

The acquisition of Intra-Cellular Therapies by Johnson & Johnson reflects a trend of larger pharmaceutical companies acquiring smaller biotech firms with promising drug candidates or technologies. This allows larger companies to expand their pipelines and market presence.

Comparison to Industry Standards

• Mergers and acquisitions in the pharmaceutical industry often involve a premium paid to the target company's shareholders.
• The $132 per share merger consideration represents a premium over Intra-Cellular Therapies' previous trading price.
• Comparable transactions include Pfizer's acquisition of Arena Pharmaceuticals and Bristol Myers Squibb's acquisition of MyoKardia, both of which involved significant premiums.

Stakeholder Impact

• Shareholders receive a cash payment of $132 per share.
• Employees' future is now tied to Johnson & Johnson's strategic plans.
• Customers may see changes in product availability or development priorities under Johnson & Johnson's ownership.

Key Dates

Keywords

merger, Intra-Cellular Therapies, Johnson & Johnson, Form 4, beneficial ownership, stock options, RSU, PRSU, Suresh K. Durgam, ITCI